MarketPulse

complete response rate

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relmada's NDV-01 Shows 76% Response Rate, Advancing Bladder Cancer Program

Relmada to present NDV-01 Phase 2 data showing 76% response rate in bladder cancer at AUA 2026 conference; Phase 3 registration trial launches mid-2026.
RLMDclinical developmentPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Protara Posts $57.4M Annual Loss as TARA-002 Bladder Cancer Data Bolsters Pipeline

Protara Therapeutics reported $57.4M full-year 2025 loss while unveiling promising 68% response rate for TARA-002 in bladder cancer trial with funding extending to 2028.
TARAfinancial resultsclinical trial